Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock

FibroGen (NASDAQ:FGEN) insider K Peony Yu sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $47.81, for a total transaction of $358,575.00. Following the transaction, the insider now directly owns 156,233 shares in the company, valued at $7,469,499.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

K Peony Yu also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Wednesday, March 14th, K Peony Yu sold 9,891 shares of FibroGen stock. The stock was sold at an average price of $53.20, for a total transaction of $526,201.20.
  • On Thursday, February 8th, K Peony Yu sold 7,500 shares of FibroGen stock. The stock was sold at an average price of $53.97, for a total transaction of $404,775.00.
  • On Monday, January 29th, K Peony Yu sold 10,000 shares of FibroGen stock. The stock was sold at an average price of $62.00, for a total transaction of $620,000.00.

FGEN stock traded down $0.75 during trading on Wednesday, hitting $48.15. 274,564 shares of the company’s stock traded hands, compared to its average volume of 591,586. The firm has a market cap of $3,918.42, a price-to-earnings ratio of -27.83 and a beta of 1.89. The company has a quick ratio of 9.70, a current ratio of 9.70 and a debt-to-equity ratio of 0.17. FibroGen has a 1 year low of $25.35 and a 1 year high of $63.00.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The company had revenue of $42.51 million for the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. analysts anticipate that FibroGen will post -1.35 EPS for the current fiscal year.

A number of equities analysts have recently commented on FGEN shares. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. TheStreet raised shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Finally, Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $66.67.

Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can increased its holdings in FibroGen by 2,097.2% during the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,041 shares during the period. Fortaleza Asset Management Inc. increased its holdings in FibroGen by 95.0% during the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 1,700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in FibroGen by 41.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 1,147 shares during the period. Oppenheimer Asset Management Inc. increased its holdings in FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares during the period. Finally, Paloma Partners Management Co purchased a new position in FibroGen during the fourth quarter valued at approximately $255,000. 61.39% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/18/insider-selling-fibrogen-fgen-insider-sells-7500-shares-of-stock.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply